

# SURVEILLANCE REPORT

## Weekly influenza surveillance overview

28 May 2010

### Main surveillance developments in week 20/2010 (17 May 2010 – 23 May 2010)

*This first page contains the main developments this week and can be printed separately or together with the more detailed information following.*

- Reports indicate that influenza activity in Europe has stabilised at low intensity with an absence of geographic spread.
- Eight (12.3%) of the 65 patients presenting with influenza-like illness to a sentinel physician tested positive for influenza, most of them for influenza virus type B and only very few for the pandemic A(H1N1) strain.
- Notwithstanding still being in pandemic Phase 6 globally, epidemiological and virological indicators are consistent with the 2009/10 influenza season coming to an end in Europe.

**Sentinel surveillance of influenza-like illness (ILI)/ acute respiratory infection (ARI):** For the twelfth consecutive week, all countries experienced low intensity. For more information, [click here](#).

**Virological surveillance:** Sentinel physicians collected 65 specimens, eight (12.3 %) of which were positive for influenza virus. For more information, [click here](#).

**Aggregate numbers of 2009 pandemic influenza (H1N1) deaths:** No deaths associated with the 2009 pandemic influenza virus were reported in week 20/2010. For more information, [click here](#).

**Hospital surveillance of severe acute respiratory infection (SARI):** Three SARI cases were reported, two of which had symptom onset during the same week. None were associated with influenza virus detection. For more information, [click here](#).

**Qualitative reporting:** For more information, [click here](#).

# Sentinel surveillance (ILI/ARI)


## Weekly analysis — epidemiology

During week 20/2010, 22 of 29 countries reported epidemiological data. For the twelfth consecutive week, all countries experienced low intensity (Map 1, Table 1).

Hungary, Latvia and the UK (Wales) reported sporadic activity, while all other countries reported no activity (Map 2, Table 1).

All countries reported a stable or decreasing trend (Table 1).

**Map 1: Intensity for week 20/2010**




\* A type/subtype is reported as dominant when > 40 % of all samples are positive for the type/subtype.

Legend:

<b>Low</b>	No influenza activity or influenza at baseline levels	-	Decreasing clinical activity
<b>Medium</b>	Usual levels of influenza activity	+	Increasing clinical activity
<b>High</b>	Higher than usual levels of influenza activity	=	Stable clinical activity
<b>Very high</b>	Particularly severe levels of influenza activity	A(H1N1)v	Type A, Subtype H1N1v
		B	Type B

**Map 2: Geographic spread for week 20/2010****Geographic spread**

- [Grey square] No Report
- [Yellow square] No Activity
- [Yellow square] Sporadic
- [Orange square] Local
- [Red square] Regional
- [Dark red square] Widespread



(C) ECDC/Dundas/TESSy

\* A type/subtype is reported as dominant when &gt; 40 % of all samples are positive for the type/subtype.

**Legend:**

<b>No activity</b>	No evidence of influenza virus activity (clinical activity remains at baseline levels)	-	Decreasing clinical activity
<b>Sporadic</b>	Isolated cases of laboratory confirmed influenza infection	+	Increasing clinical activity
<b>Local outbreak</b>	Increased influenza activity in local areas (e.g. a city) within a region, or outbreaks in two or more institutions (e.g. schools) within a region (laboratory confirmed)	=	Stable clinical activity
<b>Regional activity</b>	Influenza activity above baseline levels in one or more regions with a population comprising less than 50% of the country's total population (laboratory confirmed)	A(H1N1)v	Type A, Subtype H1N1v
<b>Widespread</b>	Influenza activity above baseline levels in one or more regions with a population comprising 50% or more of the country's population (laboratory confirmed)	B	Type B

**Table 1: Epidemiological and virological overview by country**

Country	Intensity	Geographic spread	Trend	No. of sentinel swabs	Dominant type	Percentage positive*	ILI per 100.000	ARI per 100.000	Epidemiological overview	Virological overview
Austria				0	None	-	-	-	Graphs	Graphs
Belgium	Low	No activity	Stable	4	None	0.0	21.5	1063.8	Graphs	Graphs
Bulgaria	Low	No activity	Stable	0	None	-	-	412.1	Graphs	Graphs
Cyprus				-	-	-	-	-		
Czech Republic	Low	No activity	Stable	5	None	20.0	12.8	705.7	Graphs	Graphs
Denmark	Low	No activity	Stable	0	None	-	22.2	0.0	Graphs	Graphs
Estonia	Low	No activity	Decreasing	0	None	-	1.9	158.2	Graphs	Graphs
Finland				-	-	-	-	-		
France				-	-	-	-	-		
Germany	Low	No activity	Stable	6	None	16.7	-	625.2	Graphs	Graphs
Greece	Low	No activity	Stable	0	None	-	24.6	-	Graphs	Graphs
Hungary	Low	Sporadic	Decreasing	2	None	0.0	21.4	-	Graphs	Graphs
Iceland				-	-	-	-	-		
Ireland	Low	No activity	Stable	4	None	0.0	4.0	-	Graphs	Graphs
Italy				0	B	-	-	-	Graphs	Graphs
Latvia	Low	Sporadic	Stable	0	None	-	0.0	511.6	Graphs	Graphs
Lithuania	Low	No activity	Stable	1	None	0.0	0.3	384.7	Graphs	Graphs
Luxembourg	Low	No activity	Stable	-	-	-	-*	-*	Graphs	Graphs
Malta	Low	No activity	Stable	-	-	-	-*	-*	Graphs	Graphs
Netherlands	Low	No activity	Stable	0	None	-	13.8	-	Graphs	Graphs
Norway				0	B	-	-	-	Graphs	Graphs
Poland	Low	No activity	Decreasing	1	None	0.0	27.8	-	Graphs	Graphs
Portugal	Low	No activity	Stable	0	None	-	6.7	-	Graphs	Graphs
Romania	Low	No activity	Stable	0	None	-	0.0	600.0	Graphs	Graphs
Slovakia	Low	No activity	Stable	0	None	-	102.0	1226.5	Graphs	Graphs
Slovenia	Low	No activity	Stable	3	None	0.0	0.0	725.4	Graphs	Graphs
Spain	Low	No activity	Stable	15	None	40.0	6.2	-	Graphs	Graphs
Sweden	Low	No activity	Stable	0	B	-	0.0	-	Graphs	Graphs
UK - England	Low	No activity	Stable	15	None	0.0	3.6	387.5	Graphs	Graphs
UK - Northern Ireland	Low	No activity	Stable	0	None	-	11.3	362.7	Graphs	Graphs
UK - Scotland	Low	No activity	Stable	9	A(H1N1)v	0.0	2.6	186.4	Graphs	Graphs
UK - Wales	Low	Sporadic	Stable	-	-	-	1.3	-	Graphs	Graphs
Europe				65		12.3				Graphs

\*Incidence per 100 000 is not calculated for these countries as no population denominator is provided.

Note: Liechtenstein is not reporting to the European Influenza Surveillance Network

## Description of the system

This surveillance is based on nationally organized sentinel networks of physicians, mostly general practitioners (GPs), covering at least 1–5% of the population in their countries. All EU/EEA Member States (except Liechtenstein) are participating. Depending on their country's choice, each sentinel physician reports the weekly number of patients seen with influenza-like illness (ILI), acute respiratory infection (ARI) or both to a national focal point. From the national level, both numerator and denominator data are then reported to the European Surveillance System (TESSy) database. Additional semi-quantitative indicators of intensity, geographic spread and trend of influenza activity at the national level are also reported.

# Virological surveillance

## Weekly analysis — virology

In week 20/2010, 23 countries reported virological data. Sentinel physicians collected 65 specimens, eight (12.3%) of which were positive for influenza virus (Tables 1 and 2). In addition, nine non-sentinel source specimens (i.e. specimens collected for diagnostic purpose in hospitals) were reported positive for influenza virus. Of the 17 influenza viruses detected from sentinel and non-sentinel sources during week 20/2010, 14 (82%) were type B viruses (Table 2).

Of the 16 196 type A influenza viruses detected by sentinel practices for which subtyping was performed since week 40/2009, 16 138 (99.6%) were identified as the 2009 pandemic influenza A(H1N1) virus. Table 2 shows the distribution of both sentinel and non-sentinel specimens by type and subtype. Figures 1—3 show the trends of virological detections over time. The proportion of positive sentinel samples decreased between week 46/2009 and week 07/2010 and has since stabilised towards the baseline level (Figure 3).

From week 40/2009 to week 20/2010, 3305 influenza viruses from sentinel and non-sentinel specimens were characterised antigenically (Table 3), and 1251 were characterised genetically. Of the former, 3248 (98.3%) were antigenically pandemic A/California/7/2009(H1N1)-like, and of the latter, 1229 (98.2%) belonged to the phylogenetic cluster represented by A/California/7/2009. Fifteen (75%) of the 20 influenza type B viruses antigenically characterised up to week 20/2010 were of the B/Victoria/2/87 lineage, while the remaining five (25%) were of the B/Yamagata/16/88 lineage.

More details on circulating viruses can be found in the [report](#) prepared by the Community Network of Reference Laboratories coordination team.

The latest antiviral resistance data are from week 09/2010. All pandemic viruses tested were resistant to M2 inhibitors. Of the 1453 viruses tested from nine countries, 37(2.5%) were resistant to oseltamivir, and of 1447 viruses tested, none were resistant to zanamivir (Table 4). However, the Netherlands reported a virus with reduced sensitivity to oseltamivir and zanamivir in week 14/2010.


Since the peak in week 01/2010, the total number of respiratory syncytial virus (RSV) detections has been decreasing in 11 countries (Figure 4).

**Table 2: Weekly and cumulative influenza virus detections by type, subtype and surveillance system, weeks 40/2009–20/2010**


Virus type/subtype	Current Week		Season	
	Sentinel	Non-sentinel	Sentinel	Non-sentinel
Influenza A	1	2	16877	89676
A (pandemic H1N1)	0	2	16138	78298
A (subtyping not performed)	1	0	681	11231
A (not subtypable)	0	0	14	48
A (H3)	0	0	8	48
A (H1)	0	0	36	51
Influenza B	7	7	162	357
<b>Total Influenza</b>	<b>8</b>	<b>9</b>	<b>17039</b>	<b>90033</b>


*Note:* A(pandemic H1N1), A(H3) and A(H1) includes both N-subtyped and not N-subtyped viruses.

**Figure 1: Number of sentinel specimens positive for influenza, by type, subtype and by week of report, weeks 40/2009–20/2010**



**Figure 2: Number of non-sentinel specimens positive for influenza by type, subtype and week of report, weeks 40/2009–20/2010**



**Figure 3: Proportion of sentinel samples positive for influenza, weeks 40/2009–20/2010****Table 3: Results of antigenically characterised sentinel and non-sentinel influenza virus isolates since week 40/2009**


Strain name	Number of strains
A(H1)v California/7/2009-like	3248
A(H3) A/Brisbane/10/2007 (H3N2)-like	11
A(H3) A/Perth/16/2009 (H3N2)-like	26
B/Brisbane/60/2008-like (B/Victoria/2/87 lineage)	15
B/Florida/4/2006-like (B/Yamagata/16/88 lineage)	5

**Table 4: Antiviral resistance by influenza virus type and subtype, weeks 40/2009–09/2010**

Virus type and subtype	Resistance to neuraminidase inhibitors				Resistance to M2 inhibitors	
	Oseltamivir		Zanamivir		Isolates tested	Resistant n (%)
	Isolates tested	Resistant n (%)	Isolates tested	Resistant n (%)		
A(H3N2)	0	0	0	0	0	0
A(H1N1)	0	0	0	0	0	0
A(H1N1)v	1453	37 (2.5)	1447	0	205	205 (100)
B	0	0	0	0	NA*	NA*

\* NA - not applicable, as M2 inhibitors do not act against influenza B viruses

**Figure 4: Respiratory syncytial virus (RSV) detections, sentinel and non-sentinel, weeks 40/2009–20/2010**



## Description of the system

According to the nationally defined sampling strategy, sentinel physicians take nasal or pharyngeal swabs from patients with influenza-like illness (ILI), acute respiratory infection (ARI) or both and send the specimens to influenza-specific reference laboratories for virus detection, (sub-)typing, antigenic or genetic characterisation and antiviral susceptibility testing.

For details on the current virus strains recommended by WHO for vaccine preparation [click here](#).

# Aggregate numbers of 2009 pandemic A(H1N1) associated deaths

## Weekly analysis — deaths

During week 20/2010, no deaths associated with the 2009 pandemic influenza virus were reported. Since the beginning of the pandemic, 1909 deaths have been notified to ECDC through TESSy (Table 5).

**Table 5: Aggregate numbers of 2009 pandemic A(H1N1) associated deaths, week 20/2010**

Country	Cumulative deaths since start of season	Last reported week	Deaths reported in week 20/2010
Austria	0	2009-w36	
Belgium	0	2009-w29	
Bulgaria	40	2009-w53	
Cyprus	0	2009-w29	
Czech Republic	102	2010-w20	0
Denmark	0	2009-w36	
Estonia	19	2010-w20	0
Finland	44	2010-w20	0
France	312	2010-w15	
Germany	255	2010-w20	0
Greece	149	2010-w20	0
Hungary	134	2010-w20	0
Iceland	2	2009-w52	
Ireland	26	2010-w20	0
Italy	1	2010-w14	
Latvia	34	2010-w09	
Lithuania	23	2010-w20	0
Luxembourg	3	2009-w52	
Malta	5	2010-w12	
Netherlands	62	2010-w16	
Norway	29	2010-w19	
Poland	148	2009-w53	
Portugal	0	2009-w36	
Romania	122	2010-w20	0
Slovakia	56	2010-w20	0
Slovenia	19	2010-w19	
Spain	4	2009-w29	
Sweden	24	2010-w20	0
United Kingdom	296	2010-w09	
Total	1909		0

## Description of the system

Aggregate numbers of both probable and laboratory-confirmed cases of pandemic influenza and deaths due to pandemic influenza are reported by countries still collecting this data. As countries are retrospectively updating their weekly numbers of deaths and the system calculates the cumulative values based on the current status, weekly numbers of deaths published in previous WISO editions may not always add up to the cumulative totals.

# Hospital surveillance – severe acute respiratory infection (SARI)

## Weekly analysis — SARI


During week 20/2010, three SARI cases were reported, two of which had symptom onset during the same week. None were associated with influenza virus detection. Since the beginning of SARI surveillance, 11 countries have reported 11 577 cases, including 573 fatalities (Table 6). The number of SARI cases by week of onset has been declining since the peak in week 46/2009 (Figure 5).

More than 99% of the influenza viruses detected in SARI cases since the start of the season were the 2009 pandemic influenza virus (Table 8).

**Table 6: Cumulative number of SARI cases, weeks 40/2009 - week 20/2010**

Country	Number of cases	Incidence of SARI cases per 100,000 population	Number of fatal cases reported	Incidence of fatal cases per 100,000 population	Estimated population covered
Austria	2916		41		
Belgium	1880	17.62			10668666
Cyprus	26		9		
Finland	1422	26.7	56	1.05	5326314
France	1357		302		
United Kingdom	1639	4.15	65	0.16	39503332
Ireland	903		17		
Malta	213	51.5	1	0.24	413609
Netherlands	652	3.95	29	0.18	16521505
Romania	210	16.56	13	1.02	1268418
Slovakia	359		40		
Total	11577		573		73701844

**Figure 5: Number of SARI cases by week of onset, week 20/2010**



**Table 7: Number of SARI cases by age and gender, week 20/2010**

Age groups	Male	Female
Under 2	1	
2-17		1
>=60	1	
Total	2	1

**Table 8: Number of SARI cases by influenza type and subtype, week 20/2010**

Virus type/subtype	Number of cases during current week	Cumulative number of cases since the start of the season
Influenza A		9061
A (pandemic H1N1)		9029
A(subtyping not performed)		25
A(H3)		
A(H1)		7
A(H5)		
Influenza B		
Unknown	3	2375
Total	3	11436

## Description of the system

A number of Member States carry out hospital-based surveillance of severe acute respiratory infection (SARI) exhaustively or at selected sentinel sites. SARI surveillance serves to monitor the trends in the severity of influenza and potential risk factors for severe disease to help guide preventive measures and health care resource allocation.

## Qualitative reporting

Qualitative monitoring will be an acceptable replacement for the quantitative monitoring when reliable numbers are no longer available for reporting due to overburdened surveillance systems. The qualitative components will give some indication of influenza intensity, geographic spread, trend and impact.

---

*The report text was written by an editorial team at the European Centre for Disease Prevention and Control (ECDC): Flaviu Plata, Phillip Zucs, Bruno Ciancio, Rene Snacken and Eeva Broberg. The bulletin text was reviewed by the Community Network of Reference Laboratories for Human Influenza in Europe (CNRL) coordination team: Adam Meijer, Rod Daniels, John McCauley and Maria Zambon. On behalf of the EISN members the bulletin text was reviewed by Joan O'Donnell (Health Protection Surveillance Centre, Ireland) and Katarina Prosenc (National Institute of Public Health, Slovenia).*

*Maps and commentary used in this Weekly Influenza Surveillance Overview (WISO) do not imply any opinions whatsoever of ECDC or its partners on the legal status of the countries and territories shown or concerning their borders.*

*All data published in the WISO are up-to-date on the day of publication. Past this date, however, published data should not be used for longitudinal comparisons as countries tend to retrospectively update their numbers in the database.*

*© European Centre for Disease Prevention and Control, Stockholm, 2010*